Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more
Illumina Inc (ILMN) - Net Assets
Latest net assets as of December 2025: $3.08 Billion USD
Based on the latest financial reports, Illumina Inc (ILMN) has net assets worth $3.08 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.64 Billion) and total liabilities ($3.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.08 Billion |
| % of Total Assets | 46.4% |
| Annual Growth Rate | 19.2% |
| 5-Year Change | -71.29% |
| 10-Year Change | 33.22% |
| Growth Volatility | 77.88 |
Illumina Inc - Net Assets Trend (1999–2025)
This chart illustrates how Illumina Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Illumina Inc (1999–2025)
The table below shows the annual net assets of Illumina Inc from 1999 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.08 Billion | +29.92% |
| 2024-12-31 | $2.37 Billion | -58.69% |
| 2023-12-31 | $5.75 Billion | -12.94% |
| 2022-12-31 | $6.60 Billion | -38.56% |
| 2021-12-31 | $10.74 Billion | +128.80% |
| 2020-12-31 | $4.69 Billion | +1.76% |
| 2019-12-31 | $4.61 Billion | +18.10% |
| 2018-12-31 | $3.91 Billion | +31.56% |
| 2017-12-31 | $2.97 Billion | +28.30% |
| 2016-12-31 | $2.31 Billion | +23.02% |
| 2015-12-31 | $1.88 Billion | +28.79% |
| 2014-12-31 | $1.46 Billion | -4.74% |
| 2013-12-31 | $1.53 Billion | +16.28% |
| 2012-12-31 | $1.32 Billion | +22.63% |
| 2011-12-31 | $1.08 Billion | -10.22% |
| 2010-12-31 | $1.20 Billion | +38.58% |
| 2009-12-31 | $864.25 Million | +1.84% |
| 2008-12-31 | $848.60 Million | +106.13% |
| 2007-12-31 | $411.68 Million | +66.44% |
| 2006-12-31 | $247.34 Million | +241.18% |
| 2005-12-31 | $72.50 Million | +0.33% |
| 2004-12-31 | $72.26 Million | +52.49% |
| 2003-12-31 | $47.39 Million | -33.95% |
| 2002-12-31 | $71.74 Million | -32.82% |
| 2001-12-31 | $106.79 Million | -13.95% |
| 2000-12-31 | $124.10 Million | +287.42% |
| 1999-12-31 | $32.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Illumina Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 666326500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $2.72 Billion | 100.00% |
| Total Equity | $2.72 Billion | 100.00% |
Illumina Inc Competitors by Market Cap
The table below lists competitors of Illumina Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brambles Limited
PINK:BMBLF
|
$17.99 Billion |
|
Daimler Truck Holding AG
PINK:DTGHF
|
$18.01 Billion |
|
Southwest Airlines Company
NYSE:LUV
|
$18.03 Billion |
|
Credicorp Ltd
NYSE:BAP
|
$18.04 Billion |
|
Federal National Mortgage Association Pref F
OTCQB:FNMAP
|
$17.95 Billion |
|
Telefónica S.A
PINK:TEFOF
|
$17.91 Billion |
|
TDK Corporation
PINK:TTDKF
|
$17.82 Billion |
|
Astera Labs, Inc.
NASDAQ:ALAB
|
$17.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Illumina Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,373,000,000 to 2,723,000,000, a change of 350,000,000 (14.7%).
- Net income of 850,000,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 22,000,000.
- Other factors decreased equity by 478,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $850.00 Million | +31.22% |
| Other Comprehensive Income | $-22.00 Million | -0.81% |
| Other Changes | $-478.00 Million | -17.55% |
| Total Change | $- | 14.75% |
Book Value vs Market Value Analysis
This analysis compares Illumina Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.64x to 6.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $11.36 | $120.84 | x |
| 2000-12-31 | $2.23 | $120.84 | x |
| 2001-12-31 | $1.79 | $120.84 | x |
| 2002-12-31 | $1.16 | $120.84 | x |
| 2003-12-31 | $0.74 | $120.84 | x |
| 2004-12-31 | $1.01 | $120.84 | x |
| 2005-12-31 | $0.90 | $120.84 | x |
| 2006-12-31 | $2.54 | $120.84 | x |
| 2007-12-31 | $3.80 | $120.84 | x |
| 2008-12-31 | $6.35 | $120.84 | x |
| 2009-12-31 | $6.30 | $120.84 | x |
| 2010-12-31 | $8.35 | $120.84 | x |
| 2011-12-31 | $7.74 | $120.84 | x |
| 2012-12-31 | $9.86 | $120.84 | x |
| 2013-12-31 | $10.96 | $120.84 | x |
| 2014-12-31 | $9.82 | $120.84 | x |
| 2015-12-31 | $12.41 | $120.84 | x |
| 2016-12-31 | $15.34 | $120.84 | x |
| 2017-12-31 | $19.22 | $120.84 | x |
| 2018-12-31 | $25.81 | $120.84 | x |
| 2019-12-31 | $30.96 | $120.84 | x |
| 2020-12-31 | $31.72 | $120.84 | x |
| 2021-12-31 | $71.13 | $120.84 | x |
| 2022-12-31 | $42.03 | $120.84 | x |
| 2023-12-31 | $36.36 | $120.84 | x |
| 2024-12-31 | $14.92 | $120.84 | x |
| 2025-12-31 | $17.68 | $120.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Illumina Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 31.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.58%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 2.44x
- Recent ROE (31.22%) is above the historical average (-5.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -17.23% | -1164.00% | 0.01x | 1.06x | $-8.72 Million |
| 2000 | -14.99% | -1421.31% | 0.01x | 1.07x | $-31.02 Million |
| 2001 | -23.24% | -998.51% | 0.02x | 1.15x | $-35.50 Million |
| 2002 | -56.22% | -401.70% | 0.08x | 1.70x | $-47.51 Million |
| 2003 | -57.11% | -96.53% | 0.28x | 2.09x | $-31.80 Million |
| 2004 | -8.61% | -12.31% | 0.53x | 1.31x | $-13.45 Million |
| 2005 | -28.79% | -28.40% | 0.73x | 1.39x | $-28.12 Million |
| 2006 | 16.16% | 21.65% | 0.61x | 1.22x | $15.23 Million |
| 2007 | -67.62% | -75.89% | 0.37x | 2.40x | $-319.53 Million |
| 2008 | 5.95% | 8.81% | 0.42x | 1.62x | $-34.38 Million |
| 2009 | 8.36% | 10.85% | 0.47x | 1.65x | $-14.14 Million |
| 2010 | 10.43% | 13.83% | 0.49x | 1.54x | $5.12 Million |
| 2011 | 8.06% | 8.21% | 0.48x | 2.04x | $-20.89 Million |
| 2012 | 11.47% | 13.17% | 0.45x | 1.95x | $19.40 Million |
| 2013 | 8.17% | 8.82% | 0.47x | 1.97x | $-28.01 Million |
| 2014 | 24.16% | 18.98% | 0.56x | 2.28x | $207.07 Million |
| 2015 | 24.97% | 20.79% | 0.60x | 1.99x | $276.70 Million |
| 2016 | 20.38% | 19.29% | 0.56x | 1.89x | $235.63 Million |
| 2017 | 25.53% | 26.38% | 0.52x | 1.85x | $441.60 Million |
| 2018 | 21.48% | 24.78% | 0.48x | 1.81x | $441.50 Million |
| 2019 | 21.72% | 28.28% | 0.48x | 1.59x | $540.70 Million |
| 2020 | 13.98% | 20.25% | 0.43x | 1.62x | $186.60 Million |
| 2021 | 7.09% | 16.84% | 0.30x | 1.42x | $-312.00 Million |
| 2022 | -66.74% | -96.07% | 0.37x | 1.86x | $-5.06 Billion |
| 2023 | -20.21% | -25.78% | 0.45x | 1.76x | $-1.74 Billion |
| 2024 | -51.54% | -27.97% | 0.69x | 2.66x | $-1.46 Billion |
| 2025 | 31.22% | 19.58% | 0.65x | 2.44x | $577.70 Million |
Industry Comparison
This section compares Illumina Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Illumina Inc (ILMN) | $3.08 Billion | -17.23% | 1.16x | $17.97 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |